Exploiting circulating tumor DNA (ctDNA) to intensify the adjuvant (adj) or post-adj treatment of stage III and highrisk stage II resected colon cancer patients (pts): The ERASE-CRC project by GONO

被引：0
|
作者：
Conca, V. [1 ,2 ]
Vetere, G. [1 ,2 ]
Moretto, R. [3 ]
Lonardi, S. [4 ]
Antoniotti, C. [1 ,2 ]
Germani, M. M. [1 ,2 ]
Pietrantonio, F. [5 ]
Bittoni, A. [6 ]
Carullo, M. [1 ,2 ]
Salvatore, L. [7 ]
Boccaccino, A. [8 ]
Ronzoni, M. [9 ]
Ricagno, G. [10 ]
Toma, I. [11 ]
Cupini, S. [12 ]
Latiano, T. P. [13 ]
Arcangeli, G. [14 ]
Masi, G. [1 ,2 ]
Fassan, M. [15 ]
Cremolini, C. [1 ,2 ]
机构：
[1] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy
[2] Azienda Osped Univ Pisana, Unit Med Oncol 2, Pisa, Italy
[3] Azienda Osped Univ Pisana, Unit Med Oncol 2, Pisa, Italy
[4] IOV Ist Oncol Veneto IRCCS, Dept Oncol, Med Oncol 3, Padua, Italy
[5] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[6] IRST Ist Romagnolo Studio Tumori Dino Amadori IRC, Med Oncol, Meldola, Italy
[7] Fdn Policlin Univ Agostino Gemelli IRCC, Dipartimento Oncol, Rome, Italy
[8] Santa Maria Croci Hosp Ravenna AUSL Romagana, Oncol Unit, Ravenna, Italy
[9] IRCCS Osped San Raffaele, Dept Oncol, Milan, Italy
[10] Univ Padua, Veneto Inst Oncol IOV IRCCS, Dept Surg Oncol & Gastroenterol, Med Oncol 1, Padua, Italy
[11] Tricase City Hosp, Dept Oncol & Palliat Care, Cardinale G Panico, Tricase, Italy
[12] Azienda Toscana Nord Ovest Livorno, Div Med Oncol, Dept Oncol, Livorno, Italy
[13] Fdn IRCCS Casa Sollievo Sofferenza, Dept Oncol, San Giovanni Rotondo, Italy
[14] Azienda Osped Spedali Civili Brescia, Oncol Unit, Brescia, Italy
[15] Univ Padua, Surg Pathol Unit, Dept Med DIMED, Padua, Italy
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.168
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
158TiP
引用
收藏
页码：S70 / S70
页数：1
相关论文
共 43 条
  • [21] Clinical validity of post-surgery circulating tumor DNA testing in stage III colon cancer patients treated with adjuvant chemotherapy: The PROVENC3 study
    Alarcon, Carmen Rubio
    Georgiadis, Andrew
    Franken, Ingrid A.
    Wang, Haoyue
    van Nassau, Sietske C.
    Schraa, Suzanna J.
    van der Kruijssen, Dave E.
    van Rooijen, Karlijn
    Linders, Theodora C.
    Delis-van Diemen, Pien
    Alkemade, Maartje
    Bolijn, Anne
    Tijssen, Marianne
    Lemmens, Margriet
    Meiqari, Lana
    Ketelaars, Steven L.
    Mosquera, Adria Closa
    van Dongen, Miranda M.
    Lanfermeijer, Mirthe
    Lissenberg-Witte, Birgit I.
    Bosch, Linda J.
    Bisschop-Snetselaar, Teunise
    Adriaans, Bregje
    Greer, Amy
    Riley, David
    White, James R.
    Greco, Christopher
    Cox, Liam
    Fox, Jesse
    Victor, Kaitlin
    Leech, Catherine
    Angiuoli, Samuel V.
    Kok, Niels F.
    Punt, Cornelis J.
    van den Broek, Daan
    Koopman, Miriam
    Meijer, Gerrit A.
    Velculescu, Victor E.
    Roodhart, Jeanine M.
    Coupe, Veerle M.
    Sausen, Mark
    Vink, Geraldine R.
    Fijneman, Remond J.
    CANCER RESEARCH, 2024, 84 (06)
  • [22] ACHIEVE-2 trial: A randomized phase III trial investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with high-risk stage II colon cancer (CC)
    Yoshino, T.
    Yamanaka, T.
    Shiozawa, M.
    Manaka, D.
    Kotaka, M.
    Gamoh, M.
    Shiomi, A.
    Makiyama, A.
    Munemoto, Y.
    Rikiyama, T.
    Fukunaga, M.
    Ueki, T.
    Shitara, K.
    Shinkai, H.
    Tanida, N.
    Yamazaki, K.
    Sunami, E.
    Ohtsu, A.
    Maehara, Y.
    ANNALS OF ONCOLOGY, 2019, 30
  • [23] Is there evidence of diminishing disparities in treatment (tx) with adjuvant (adj) chemotherapy (Ch) among elderly (E) stage 3 colon cancer (CC) patients (pts)? An analysis of 8,374 pts from SEER-Medicare data
    Davidoff, A. J.
    Choti, M. A.
    Zuckerman, I. H.
    Obeidat, N.
    Rapp, T.
    Onukwugha, E.
    Sullivan, P.
    Gardner, J. F.
    Mullins, C. D.
    Hanna, N. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] Prognostic value of circulating tumor DNA (ctDNA) detection during adjuvant chemotherapy in patients with stage III colorectal cancer: The interim report of a prospective, observational study
    Peng, Junjie
    Li, Yaqi
    Mo, Shaobo
    Ma, Xiaoji
    Hu, Xiang
    Zhang, Long
    Huang, Dan
    Cai, Sanjun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [25] The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217)
    Folprecht, Gunnar
    Reinacher-Schick, Anke
    Weitz, Juergen
    Lugnier, Celine
    Kraeft, Anna-Lena
    Wisser, Sarah
    Aust, Daniela E.
    Weiss, Lukas
    von Bubnoff, Nikolas
    Kramer, Michael
    Thiede, Christian
    Tannapfel, Andrea
    CLINICAL COLORECTAL CANCER, 2022, 21 (02) : 170 - 174
  • [26] Clinical implementation of the universal tumor screening with the mismatch repair (MMR) proteins on decision impact of adjuvant chemotherapy in patients with resected stage II/III colorectal cancer (CRC)
    Yamamoto, Y.
    Tsukada, Y.
    Bando, H.
    Sasaki, T.
    Nishizawa, Y.
    Kojima, M.
    Kuwata, T.
    Ito, M.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] MEDOCC-CrEATE trial in progress: effectiveness of adjuvant chemotherapy in stage II colon cancer patients with positive circulating tumor DNA.
    Schraa, Suzanna J.
    Van Rooijen, Karlijn L.
    Van der Kruijssen, Dave E.
    Alarcon, Carmen Rubio
    Phallen, Jillian
    Simmons, John
    Angiuoli, Sam
    Greer, Amy E.
    Coupe, Veerle M.
    Van Grevenstein, Helma M.
    Elias, Sjoerd
    Verkooijen, Helena M.
    Van Dongen, Miranda M.
    Bosch, Linda J.
    Van den Broek, Daan
    Meijer, Gerrit A.
    Velculescu, Victor E.
    Fijneman, Remond J.
    Vink, Geraldine R.
    Koopman, Miriam
    CANCER RESEARCH, 2021, 81 (13)
  • [28] Phase II results of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) phase II/III study.
    Morris, Van K.
    Yothers, Greg
    Kopetz, Scott
    Puhalla, Shannon L.
    Lucas, Peter C.
    Iqbal, Atif
    Boland, Patrick M.
    Deming, Dustin A.
    Scott, Aaron J.
    Lim, Howard J.
    Jacobs, Samuel A.
    Hong, Theodore S.
    Wolmark, Norman
    George, Thomas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 5 - 5
  • [29] MEDOCC-CrEATE trial: Feasibility of measuring circulating tumor DNA after surgery to guide adjuvant chemotherapy in stage II colon cancer patients
    Franken, Ingrid
    Schraa, Suzanna
    van Rooijen, Karlijn
    van der Kruijssen, Dave
    Rubio-Alarcon, Carmen
    Ketelaars, Steven
    van Nassau, Sietske
    Snetselaar, Teunise
    Adriaans, Bregje
    Phallen, Jillian
    Angiuoli, Sam
    Greer, Amy
    Verner, Ellen
    Coupe, Veerle
    Verkooijen, Helena
    van Dongen, Miranda
    Bosch, Linda
    Lanfermeijer, Mirthe
    van den Broek, Daan
    Meijer, Gerrit
    Velculescu, Victor
    Sausen, Mark
    Koopman, Miriam
    Fijneman, Remond
    Vink, Geraldine
    CANCER RESEARCH, 2024, 84 (06)
  • [30] Circulating tumor DNA-based decision for adjuvant treatment in colon cancer stage II evaluation: (CIRCULATE-trial) AIO-KRK-0217
    Folprecht, Gunnar
    Reinacher-Schick, Anke
    Tannapfel, Andrea
    Weitz, Juergen
    Kossler, Thibaud
    Weiss, Lukas
    Aust, Daniela Ellen
    von Bubnoff, Nikolas
    Kramer, Michael
    Thiede, Christian
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345